NOXXON Initiates Phase IIa Study of Anti-Hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) in Dialysis Patients with EPO-hyporesponsive Anemia
NOXXON Pharma today announced the treatment of a first patient with its anti-hepcidin Spiegelmer® lexaptepid pegol (NOX-…